Short Interest in Kiromic BioPharma, Inc. (NASDAQ:KRBP) Declines By 40.5%

Kiromic BioPharma, Inc. (NASDAQ:KRBPGet Rating) saw a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 198,000 shares, a decrease of 40.5% from the March 15th total of 333,000 shares. Based on an average daily volume of 282,300 shares, the short-interest ratio is currently 0.7 days.

A number of large investors have recently added to or reduced their stakes in the stock. LPL Financial LLC increased its holdings in Kiromic BioPharma by 59.8% in the fourth quarter. LPL Financial LLC now owns 84,400 shares of the company’s stock worth $129,000 after buying an additional 31,600 shares during the last quarter. K.J. Harrison & Partners Inc increased its holdings in Kiromic BioPharma by 54.3% in the fourth quarter. K.J. Harrison & Partners Inc now owns 26,233 shares of the company’s stock worth $40,000 after buying an additional 9,231 shares during the last quarter. Zeke Capital Advisors LLC increased its holdings in Kiromic BioPharma by 236.7% in the third quarter. Zeke Capital Advisors LLC now owns 56,899 shares of the company’s stock worth $175,000 after buying an additional 40,000 shares during the last quarter. Intellectus Partners LLC increased its holdings in Kiromic BioPharma by 32.0% in the third quarter. Intellectus Partners LLC now owns 98,850 shares of the company’s stock worth $303,000 after buying an additional 23,950 shares during the last quarter. Finally, 1492 Capital Management LLC increased its holdings in Kiromic BioPharma by 21.3% in the third quarter. 1492 Capital Management LLC now owns 434,408 shares of the company’s stock worth $1,334,000 after buying an additional 76,402 shares during the last quarter. Hedge funds and other institutional investors own 15.86% of the company’s stock.

Shares of KRBP opened at $0.84 on Friday. The company has a market capitalization of $13.05 million, a price-to-earnings ratio of -0.99 and a beta of 0.16. Kiromic BioPharma has a fifty-two week low of $0.57 and a fifty-two week high of $11.00. The business’s 50-day moving average is $0.80 and its 200-day moving average is $1.61.

Kiromic BioPharma (NASDAQ:KRBPGet Rating) last issued its earnings results on Friday, March 11th. The company reported ($0.40) earnings per share for the quarter. On average, equities analysts predict that Kiromic BioPharma will post -1.45 earnings per share for the current year.

Kiromic BioPharma Company Profile (Get Rating)

Kiromic BioPharma, Inc, a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy.

See Also

Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.